Journal Mobile Options
Table of Contents
Vol. 9, No. 5, 2009
Issue release date: November 2009
Pancreatology 2009;9:583–600

A Fuller Understanding of Pancreatic Neuroendocrine Tumours Combined with Aggressive Management Improves Outcome

Ong S.L. · Garcea G. · Pollard C.A. · Furness P.N. · Steward W.P. · Rajesh A. · Spencer L. · Lloyd D.M. · Berry D.P. · Dennison A.R.
Departments of aHepatobiliary and Pancreatic Surgery, bHistopathology and cRadiology, Leicester General Hospital, dDepartment of Oncology, University Hospitals of Leicester, and eDepartment of Hepatobiliary and Pancreatic Surgery, Leicester Royal Infirmary, Leicester, UK

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Neuroendocrine tumours of the pancreas (PNETs) represent 1–2% of all pancreatic tumours. The terms ‘islet cell tumours’ and ‘carcinoids’ of the pancreas should be avoided. The aim of this review is to offer an overview of the history and diagnosis of PNETs followed by a discussion of the available treatment options. Methods: A search on PubMed using the keywords ‘neuroendocrine’, ‘pancreas’ and ‘carcinoid’ was performed to identify relevant literature over the last 30 years. Results: The introduction of a revised classification of neuroendocrine tumours by the World Health Organisation (WHO) in 2000 significantly changed our understanding of and approach to the management of these tumours. Advances in laboratory and radiological techniques have also led to an increased detection of PNETs. Surgery remains the only treatment that offers a chance of cure with increasing number of non-surgical options serving as beneficial adjuncts. The better understanding of the behaviours of PNETs together with improvements in tumour localisation has resulted in a more aggressive management strategy with a concomitant improvement in symptom palliation and a prolongation of survival. Conclusion: Due to their complex nature and the wide range of therapeutic options, the involvement of specialists from all necessary disciplines in a multidisciplinary team setting is vital to provide optimal treatment of this disease.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Oberg K, Eriksson B: Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005;19:753–781.
  2. Kang C, Park S, Kim K, Choi J, Lee W, Kim B: Surgical experiences of functioning neuroendocrine neoplasm of the pancreas. Yonsei Med J 2006;47:833–839.
  3. Eriksson B, Oberg K: Neuroendocrine tumours of the pancreas. Br J Surg 2000;87:128–131.

    External Resources

  4. Fitzgerald T, Hickner Z, Schmitz M, Seah A, Kort E: Increasing incidence of nonfunctional neuroendocrine tumours of the pancreas. American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, 2007.
  5. Bartsch D, Langer P, Wild A, Schilling T, Celik I, Rothmund M, et al: Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance? Surgery 2000;128:958–966.
  6. Grama D, Skogseid B, Wilander E, Eriksson B, Martensson H, Cedermark B, et al: Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment. World J Surg 1992;16:611–618.
  7. Libutti S, Chouyke P, Alexander H, Glenn G, Bartlett D, Zbar B, et al: Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery 2000;128:1022–1027.
  8. Alexakis N, Connor S, Ghaneh P, Lombard M, Smart H, Evans J, et al: Hereditary pancreatic endocrine tumours. Pancreatology 2004;4:417–433.
  9. Francalanci P, Diomedi-Camassei F, Purificato C, Santorelli F, Giannotti A, Dominici C, et al: Malignant pancreatic endocrine tumor in a child with tuberous sclerosis. Am J Surg Pathol 2003;27:1386–1389.
  10. Stephen A, Hodin R: Neuroendocrine tumors of the pancreas, excluding gastrinoma. Surg Oncol Clin North Am 2006;15:497–510.
  11. Langley K: The neurotransmitter concept today. Ann NY Acad Sci 1994;733:1–17.
  12. Portela-Gomes G, Hacker G, Weitgasser R: Neuroendocrine cell markers for pancreatic islets and tumours. Appl Immunohisto- chem Mol Morphol 2004;12:183–192.
  13. Regitnig P, Spuller E, Denk H: Insulinoma of the pancreas with insular-ductular differenctiation in its liver metastasis – indication of a common stem-cell origin of the exocrine and endocrine components. Virchows Arch 2001;438:624–628.
  14. Arnold R: Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 2005;19:491–505.
  15. Nicholls A: Simple adenoma of pancreas arising from an islet of Langerhans. J Med Res 1902;8:385–395.

    External Resources

  16. Oberndorfer S: Karzinoide Tumoren des Dünndarms. Frankf Z Pathol 1907;1:426.
  17. Pearse A: The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 1969;17:303–313.
  18. Kloppel G, Perren A, Heitz P: The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 2004;1014:13–27.
  19. Solcia E, Kloppel G, Sobin L, et al: Histologic Typing of Endocrine Tumours, ed 2. Berlin, Springer, 2000.
  20. Crocetti E, Paci E: Malignant carcinoids in the USA, SEER 1992–1999. An epidemiological study with 6,830 cases. Eur J Cancer Prev 2003;12:191–194.
  21. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder W, et al: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395–401.
  22. Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, et al: Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 2008;95:627–635.
  23. Schurr PG, Strate T, Rese K, Kaifi JT, Reichelt U, Petri S, et al: Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg 2007;245:273–281.
  24. de Herder W: Biochemistry of neuroendocine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:33–41.
  25. Eriksson B, Oberg K, Stridsberg M: Tumor markers in neuroendocrine tumors. Digestion 2000;62(suppl 1):33–38.
  26. Guo Y, Townsend CJ: Roles of gastrointestinal hormones in pancreatic cancer. J Hepatobiliary Pancreat Surg 2000;7:276–285.
  27. Nash S, Said J: Gastroenteropancreatic neuroendocrine tumors. A histochemical and immunohistochemical study of epithelial (keratin proteins, carcinoembryonic antigen) and neuroendocrine (neuron-specific enolase, bombesin and chromogranin) markers in foregut, midgut, and hindgut tumors. Am J Clin Pathol 1986;86:415–422.
  28. Lyons D, Eisen B, Clark M, Pysher T, Welsh J, Kem D: Concurrent Cushing’s and Zollinger-Ellison syndromes in a patient with islet cell carcinoma. Case report and review of the literature. Am J Med 1984;76:729–733.
  29. Heitz P, Kasper M, Polak J, Kloppel G: Pancreatic endocrine tumors. Hum Pathol 1982;13:263–271.
  30. O’Grady H, Conlon K: Pancreatic neuroendocrine tumours. Eur J Surg Oncol 2008;34:324–332.
  31. Warner R: Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology 2005;128:1668–1684.
  32. O’Connor D, Deftos L: Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986;314:1145–1151.
  33. Nobels F, Kwekkeboom D, Coopmans W, et al: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997;82:2622–2628.
  34. Barakat M, Meeran K, Bloom S: Neuroendocrine tumours. Endocr Relat Cancer 2004;11:1–18.
  35. Yasuda D, Iguchi H, Funakoshi A, Wakasugi H, Sekiya K, Misawa T, et al: Comparison of plasma pancreastatin and GAWK concentrations, presumed processing products of chromogranin A and B, in plasma of patients with pancreatic islet cell tumors. Horm Metab Res 1993;25:593–595.
  36. Yeo C: Neoplasms of the endocrine pancreas; in Greenfield L, Mulholland M, Oldham K, et al: Surgery: Scientific Principles and Practice, ed 3. Philadelphia, Lippincott, 2001, pp 899–913.
  37. Piovesan A, Pia A, Visconti G, et al: Proinsulin-secreting neuroendocrine tumor of the pancreas. J Endocrinol Invest 2003;26:758–761.
  38. Shimizu T, Sasakuma F, Ishikawa O, et al: Assessment of immunoassays for insulin in diagnostic tests for insulinoma. Diabetes Res Clin Pract 2003;26:149–154.

    External Resources

  39. Vezzosi D, Bennet A, Fauvel J, et al: Insulin levels measured with an insulin-specific assay in patients with fasting hypoglycaemia related to endogenous hyperinsulinism. Eur J Endocrinol 2003;149:413–419.
  40. Dockray G: Clinical endocrinology and metabolism. Gastrin. Best Pract Res Clin Endocrinol Metab 2004;18:555–568.
  41. Kaltsas G, Besser G, Grossman A: The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458–511.
  42. Anderson M, Carpenter S, Thompson N, et al: Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000;95:2271–2277.
  43. Brandle M, Pfammatter T, Spinas G, et al: Assessment of selective arterial calcium stimulation and hepatic venous sampling to localize insulin-secreting tumours. Clin Endocrinol 2001;55:357–362.
  44. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, et al: Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617–1626.
  45. Debray M, Geoffroy O, Laissy J, et al: Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol 2001;74:1065–1070.
  46. Eriksson B, Bergstrom M, Sundin A, et al: The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann NY Acad Sci 2002;970:159–169.
  47. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman A: Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004;151:15–27.
  48. Lebtahi R, Cardiot G, Delahaye N, et al: Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med 1999;49:1602–1608.
  49. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;15:966–973.
  50. Rosch T, Lighdale C, Botet J, et al: Localization of gastrinomas by endoscopic ultrasonography. N Engl J Med 1992;326:1721–1726.
  51. van Hoe L, Gryspeerdt S, Marchal G, et al: Helical CT for the preoperative localisation of islet cell tumors of the pancreas: value of arterial and parenchymal phase images. Am J Roentgenol 1995;165:1437–1439.
  52. Frankel W: Update on pancreatic endocrine tumors. Arch Pathol Lab Med 2006;130:963–966.
  53. Tomita T: Immunocytochemical localization of prohormone convertase 1/3 and 2 in pancreatic islet cells and islet cell tumors. Pancreas 2001;23:172–176.
  54. Schmid K, Brink M, Freytag G, et al: Expression of chromogranin A and B and secretoneurin immunoreactivity in neoplastic and nonneoplastic pancreatic alpha cells. Virchows Arch 1994;425:127–132.
  55. Schmechel D, Marangos P, Brightman M: Neuron-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature 1978;276:834–836.
  56. Portela-Gomes G, Grimelius L, Johansson H, et al: Chromogranin A in human neuroendocrine tumors. An immunohistochemical study with region-specific antibodies. Am J Surg Pathol 2001;25:1261–1267.
  57. Portela-Gomes G, Lukinius A, Grimelius L: Synaptic vesicle protein 2: a new neuroendocrine cell marker. Am J Clin Pathol 2000;157:1299–1309.
  58. Portela-Gomes G, Stridsberg M, Johansson H, et al: Co-localization of synaptophysin with different neuroendocrine hormones in the human gastrointestinal tract. Histochem Cell Biol 1999;111:49–54.
  59. Portela-Gomes G, Stridsberg M, Johansson H, et al: Complex co-localization of chromogranins and neurohormones in the human gastrointestinal tract. J Histochem Cytochem 1997;45:815–822.
  60. Oda Y, Tanaka Y, Naruse T, et al: Expression of somatostatin receptor and effects of somatostatin analogue on pancreatic endocrine tumors. Surg Today 2002;32:690–694.
  61. Papoti M, Bongiovanni M, Volante M, et al: Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002;440:461–475.
  62. Kulaksiz H, Eissele R, Rossler D, et al: Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002;50:52–60.
  63. Cohen T, Herzog Y, Brodzky A, et al: Neuropilin-2 is a novel marker expressed in pancreatic islet cells and endocrine pancreatic tumours. J Pathol 2002;198:77–82.
  64. Heitz P, Komminoth P, Perren A, et al: Tumors of the endocrine pancreas; in DeLellis R, Lloyd R, Heitz P, Eng C (eds): Pathology and Genetics of Tumours of Endocrine Organs. Lyon, IARC Press, 2004, pp 175–208.
  65. Ferrone C, Tang L, Tomlinson J, Gonene M, Hochwald S, Brennan M, et al: Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 2007;25:5609–5615.
  66. Moesta KT, Schlag P: Proposal for a new carcinoid tumour staging system based on tumour tissue infiltration and primary metastasis; a prospective multicentre carcinoid tumour evaluation study. West German Surgical Oncologists’ Group. Eur J Surg Oncol 1990;16:280–288.
  67. La Rosa S, Sessa F, Capella C, et al: Prognostic criteria in nonfunctioning pancreatic endocrine tumors. Virch Arch 1996;429:323–333.
  68. Hochwald S, Zee S, Conlon K, et al: Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20:2633–2642.
  69. Chung J, Choi D, Jo S, Heo J, Choi S, Kim Y: Malignant nonfunctioning endocrine tumors of the pancreas: predictive factors for survival after surgical treatment. World J Surg 2007;31:579–585.
  70. Bahra M, Jacob D, Pascher A, Plockinger U, Kristiansen G, Neuhaus P, et al: Surgical strategies and predictors of outcome for malignant neuroendocrine tumors of the pancreas. J Gastroenterol Hepatol 2007;22:930–935.
  71. Shan Y, Sy E, Lin P: Role of somatostatin in the prevention of pancreatic stump-related morbidity following elective pancreaticoduodenenctomy in high-risk patients and elimination of surgeon-related factors: prospective, randomized, controlled trial. World J Surg 2003;27:709–714.
  72. Friess H, Buchler M: Efficacy of somatostatin and its analogues in pancreatic surgery and pancreatic disorders. Digestion 1996;57(suppl 1):97–102.
  73. Crippa S, Basi C, Warshaw A, Falconi M, Partelli S, Thayer S, et al: Middle pancreatectomy: indications, short- and long-term operative outcomes. Ann Surg 2007;246:69–76.
  74. Dalton R, Sarr M, van Heerden J, Colby T: Carcinoma of the body and tail of the pancreas: is curative resection justified? Surgery 1992;111:489–494.
  75. Yeo C, Wang B, Anthone G, Cameron J: Surgical experience with pancreatic islet-cell tumors. Arch Surg 1993;128:1143–1148.
  76. Thompson G, van Heerden J, Grant C, Carney J, Ilstrup D: Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery 1988;104:1011–1017.
  77. Matthews B, Smith T, Kercher K, Holder WJ, Heniford B: Surgical experience with functioning pancreatic neuroendocrine tumors. Am Surg 2002;68:660–665.
  78. Lo C, van Heerden J, Thompson G, Grant C, Soreide J, Harmsen W: Islet cell carcinoma of the pancreas. World J Surg 1996;20:878–883.
  79. Guo K, Liao H, Tian Y, Guo R, He S, Shen K: Surgical treatment of nonfunctioning islet cell tumor: report of 41 cases. Hepatobiliary Pancreat Dis Int 2004;3:469–472.

    External Resources

  80. Cheslyn-Curtis S, Sitaram V, Williamson R: Management of non-functioning neuroendocrine tumours of the pancreas. Br J Surg 1993;80:625–627.
  81. Boukhman M, Karam J, Shaver J, Siperstein A, Duh Q, Clark O: Insulinoma – experience from 1950–1995. Western J Med 1998;169:98–104.
  82. Billimoria K, Tomlinson J, Merkow R, Stewart A, Ko C, Talamonti M, et al: Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg 2007;11:1460–1467.
  83. Norton J, Warren R, Kelly M, Zuraek M, Jensen R: Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003;134:1057–1063.
  84. Sarmiento J, Heywood G, Rubin J, Ilstrup D, Nagorney D, Que F: Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003;197:29–37.
  85. Chamberlain R, Canes D, Brown K, Saltz L, Jarnagin W, Fong Y, et al: Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190:432–445.
  86. Munsunuru S, Chen H, Rajpal S, Stephani N, McDermott J, Holen K, et al: Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg 2006;141:1000–1004.
  87. Falconi M, Bettini R, Boninsegna L, Crippa S, Butturini G, Pederzoli P: Surgical strategy in the treatment of pancreatic neuroendocrine tumors. J Pancreas 2006;7:150–156.

    External Resources

  88. Cahlin C, Friman S, Ahlman H, Backman L, Mjornstedt L, Lindner P, et al: Liver transplantation for metastatic neuroendocrine tumor disease. Transplant Proc 2003;35:809–810.
  89. Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S, et al: Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumours. Liver Transplant 2007;13:327–333.
  90. Marin C, Robles R, Fernandez J, Bueno F, Ramirez P, Miras M, et al: Role of liver transplantation in the management of unresectable neuroendocrine liver metastases. Transplant Proc 2007;39:2302–2303.
  91. Lang H, Schlitt H, Schmidt H, Felemming P, Nashan B, Scheumann G, et al: Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas – a single center experience with ten patients. Langenbecks Arch Surg 1999;384:370–377.
  92. Aparicio T, Ducreux M, Baudin E, Sabourin J, De Baere T, Mitry E, et al: Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001;37:1014–1019.
  93. Lamberts S, van der Lely A, de Herder W, et al: Octreotide. N Engl J Med 1996;334:246–254.
  94. Hubina E, Nanzer A, Hanson M, Ciccarelli E, Losa M, Gaia D, et al: Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 2006;155:371–379.
  95. Kwekkeboom D, Bakker W, Kooij P, et al: [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001;28:1319–1325.
  96. Slooter G, Breeman W, Marquet R, Krenning E, van Eijck C: Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer 1999;81:767–771.
  97. Kwekkeboom D, Teunissen J, Bakker W, Kooij P, de Herder W, Feelders R, et al: Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754–2762.
  98. Arnold R, Rinke A, Schmidt C, Hofbauer L: Endocrine tumours of the gastrointestinal tract: chemotherapy. Best Pract Res Clin Gastroenterol 2005;19:649–656.
  99. Delaunoit T, Neczyporenko F, Rubin J, Erlichman C, Hobday T: Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol 2008;103:475–483.
  100. O’Toole D, Hentic O, Corcos O, Ruszniewski P: Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 2004;80(suppl 1):79–84.
  101. Moertel C, Lefkopoulos M, Lipsitz M: Streptozocin-doxurubicin, streptozocin-fluorouracil of chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519–523.
  102. Ramanathan R, Cnaan A, Hahn R, et al: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001;12:1139–1143.
  103. Bajetta E, Rimasa L, Camaghi C, et al: 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998;83:372–378.
  104. Mitry E, Baudin E, Ducreux M, Sabourin J, Rufie P, Aparicio T, et al: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351–1355.
  105. Moertel C, Kvols L, O’Connell M, Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227–232.
  106. Moertel C, Rubin J, O’Connell M: Phase II study of cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Treatment Rep 1986;70:1459–1460.
  107. Arnold R, Rinke A, Schmidt C, Hofbauer L: Chemotherapy. Best Pract Res Clin Gastroenterol 2005;19:649–656.
  108. Di Bartolomeo M, Bajetta E, Bochicchio AM, et al: A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trial in Medical Oncology (I.T.M.O.) Group. Ann Oncol 1995;6:77–79.
  109. Oberg K: Interferon in the management of neuroendocrine GEP-tumours. Digestion 2000;62(suppl 1):92–97.

    External Resources

  110. Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsodi J, et al: Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 1980;284:316–320.
  111. Dirix L, Vermeulen P, Fierens H, De Schepper B, Corthouts B, Van Oosterom A: Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors – an antiangiogenic effect? Anticancer Drugs 1996;7:175–181.
  112. Oberg K, Eriksson B: The role of interferons in the management of carcinoid tumours. Br J Haematol 1991;79(suppl 1):74–77.
  113. Faiss S, Pape U, Bohmig M, Dorffel Y, Mansmann U, Golder W, et al: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003;21:2689–2696.
  114. Fazio N, de Braud F, Delle Fave G, Oberg K: Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination. Ann Oncol 2007;18:13–19.
  115. Fjallskog M, Sundin A, Westlin J, Oberg K, Janson E, Eriksson B: Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol 2002;19:35–42.
  116. Simon P, Spilcke-Liss E, Wallschofski H: Endocrine tumors of the pancreas. Endocrinol Metab Clin North Am 2006;35:431–447.
  117. Hocker M, Wiedenmann B: Therapeutic and diagnostic implications of the somatostatin system in gastroenteropancreatic neuroendocrine tumour disease. Ital J Gastroenterol Hepatol 1999;31(suppl 2):S139–S142.

    External Resources

  118. de Herder W, Krenning E, van Eijck C, Lamberts S: Considerations concerning a tailored individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas. Endocr Relat Cancer 2004;11:19–34.
  119. Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller-Brand J, et al: Treatment with 90Y-and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 2006;140:968–977.
  120. O’Toole D, Maire F, Ruszniewski P: Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer 2003;10:463–468.
  121. Garren S, Muhs A, Bui J, Blend M, Owens C, Helton W, et al: Complete eradication of hepatic metastasis from colorectal cancer by Yttrium-90 SIRT. World J Gastroenterol 2007;13:3016–3019.

    External Resources

  122. van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, et al: Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. J Surg Oncol 2004;88:78–85.
  123. Gulec S, Mesoloras G, Dezarn W, McNeillie P, Kennedy A: Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med 2007;5:15.
  124. Gale N, Yancopoulos G: Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999;13:1055–1066.
  125. Wood J, Bold G, Buchdunger E, et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178–2189.
  126. Mross K, Drevs J, Muller M, Medinger M, Marme D, Hennig J, et al: Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 2005;41:1291–1299.
  127. Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, et al: Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol 2006;57:761–771.
  128. Izzedine H, Buhaescu I, Rixe O, Deray G: Sunitinib malate. Cancer Chemother Pharmacol 2007;60:357–364.
  129. Hess-Stumpp H, Haberey M, Thierauch KH: PTK787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumour growth with high efficacy. Chembiochem 2005;6:550–557.
  130. Chen H, Hardacre J, Uzar A, Cameron J, Choti M: Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998;187:88–92.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50